ClinicalTrials.gg
RecruitingNCT06856733Opi-PrimUpdated Sep 30, 2026

Improved Treatment for Patients With Long-term Opioid Therapy for Non-cancer Pain in Primary Care

An interventional study of Person-centred team-based approach in Chronic Pain, Chronic Pain Management and Primary Care, sponsored by Uppsala County Council, Sweden. Recruiting at 4 sites in Sweden. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Uppsala County Council, Sweden · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Sep 30, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Chronic Pain with a site in Sweden — 30 open to participants now, 37 under way, none of them phase 3. Chronic Pain · Sweden.

Planned enrollment
27th of 65
110 · median 80
Started
2025
with 8 others
No phase
61 of 88
23 open now
Primary completion
2028-06
later than 28 of 36 live
Registered
72nd of 88
by date

Among the 88 studies in Chronic Pain with a site in Sweden, this one is the 27th largest by planned enrollment of the 65 interventional ones that give a count, is one of 9 that started in 2025, is one of 61 with no phase, reaches primary completion later than 28 of the 36 other live ones, and was the 72nd registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

30 of the 88 studies in Chronic Pain with a site in Sweden are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Chronic Pain with a site in Sweden, or all of them as a file.
02

Study summary

The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:

What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?

Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.

Participants will receive a person-centred team-based treatment consisting of:

  • Phase 1 (investigation and assessment, week 1-3): A medication review, pain analysis and other assessments through separate visits to a pharmacist, general practitioner, physiotherapist, psychologist and care manager
  • Phase 2 (treatment plan, week 3-4): A team consultations with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made based.
  • Phase 3 (treatment and follow-up, week 4-24): Implementation of the individualized rehabilitation plan with frequent follow-up contacts (1 per 1-3 weeks) by phone with the care manager.
Read the detailed description

The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.

Primary objective:

To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care

Trial design and setting:

This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).

This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.

Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.

03

Conditions studied

  • Chronic Pain
  • Chronic Pain Management
  • Primary Care

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having received the equivalent of 90 days or more prescription of opioids for chronic pain made by the general practitioner during the recent 12 months
  • Able to speak Swedish or English

Exclusion criteria

Exclusion Criteria:

  • Having been referred to a pain clinic (either at hospital or multimodal rehabilitation in primary care) within the last 6 months
  • No current opioid use, severe cognitive dysfunction, e.g., suicidal ideation, psychotic symptoms, or dementia, that prevents .
  • Using their opioids for cancer pain
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • No intervention
    Control

    Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.

  • Active comparator
    Intervention

    Phase 1 (investigation and assessment, week 1-3): * A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist. * A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms. * A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities. * A visit to a psychologist for diagnostics and treatments regarding psychological and social factors. * A visit to a care manager Phase 2 (treatment plan, week 3-4): \- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24): * Implementation of the individualized rehabilitation plan. * Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager. * A second team consultation half-way

    Behavioral: Person-centred team-based approach

Interventions

  • BehavioralPerson-centred team-based approach

    Phase 1 (investigation and assessment, week 1-3): * A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist. * A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms. * A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities. * A visit to a psychologist for diagnostics and treatments regarding psychological and social factors. * A visit to a care manager Phase 2 (treatment plan, week 3-4): \- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24): * Implementation of the individualized rehabilitation plan. * Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager. * A second team consultation half-way

06

What researchers measure

Primary outcomes

  1. Pain interference

    Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

    Time frame: The primary outcome measure will be the difference in mean pain interference after 6 months.

Secondary outcomes

  1. Pain intensity

    Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse

    Time frame: After 3, 6 and 12 months

  2. Symptoms of depression

    Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse

    Time frame: After 3, 6 and 12 months

  3. Symptoms of anxiety

    Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse

    Time frame: After 3, 6 and 12 months

  4. Patient satisfaction

    Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse

    Time frame: After 3, 6 and 12 months

  5. Quality of life according to the 5-level EuroQol 5D

    Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse.

    Time frame: After 3, 6 and 12 months

  6. Opioid use

    Measured with as morphine equivalents: in mg.

    Time frame: After 3, 6 and 12 months

  7. Symptoms of withdrawal

    Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse

    Time frame: After 3, 6 and 12 months

  8. Pain interference

    Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.

    Time frame: After 3 and 12 months

07

Study locations

2 of 4 sites recruiting
08

References and documents

Publications

  • Svensson A, Ljungvall H, Kempen T, Kalvemark-Sporrong S, Peterson M. The constant conflicts of opioid prescribing - GPs' views on treating chronic pain with opioids in primary care: a reflexive qualitative analysis. Scand J Prim Health Care. 2026 Dec;44(1):2665697. doi: 10.1080/02813432.2026.2665697. Epub 2026 May 5. PubMed 42083502 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2028, 39 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 39 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2028 → Jun 2028 and completion Jun 2029 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 4, 2025
StartActual
Mar 10, 2025
Primary completionEst.
Jun 30, 2028was Dec 2028
CompletionEst.
Dec 31, 2028was Jun 2029
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (2 Sweden)
  • Region Gävleborg · Gävle, Sweden
  • Region Sörmland · Strängnäs, Sweden
Show 1 removed
  • Region Sörmland · Strängnäs, Sweden
Sep 30, 2026
Primary completion
Dec 31, 2028→Jun 30, 2028
Sep 30, 2026
Study completion
Jun 30, 2029→Dec 31, 2028
Sep 30, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Region Uppsala · Uppsala, SwedenContact a•••@uu.se · •••6400→a•••@uu.se · •••6400
  • Region Örebro Län · Örebro, SwedenContact e•••@regionorebrolan.se · •••5260→e•••@regionorebrolan.se · •••5260
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    2 sites added, 1 site removed
    Show 2 added (2 Sweden)
    • Region Gävleborg · Gävle, Sweden
    • Region Sörmland · Strängnäs, Sweden
    Show 1 removed
    • Region Sörmland · Strängnäs, Sweden
    Primary completion Dec 31, 2028→Jun 30, 2028
    Study completion Jun 30, 2029→Dec 31, 2028
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Region Uppsala · Uppsala, SwedenContact a•••@uu.se · •••6400→a•••@uu.se · •••6400
    • Region Örebro Län · Örebro, SwedenContact e•••@regionorebrolan.se · •••5260→e•••@regionorebrolan.se · •••5260
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06856733
Lead sponsor
Uppsala County Council, Sweden
Collaborators
Uppsala University, Örebro University, Sweden, Sormland County Council, Sweden, Örebro County Council
Responsible party
Thomas Kempen (Assistant professor, Uppsala County Council, Sweden) — Principal investigator
First posted
Mar 4, 2025
Start date
Mar 10, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Magnus Peterson, PhD, MD
Contact
magnus.peterson@regionuppsala.se
+46702882768
Anna Svensson, MD
Contact
anna.k.svensson@uu.se
+46702206400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion